HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 1,549-1,560 of 1,811
Other study type icon
CompletedNCT07150078

Dual Task and Attention Deficit and Hyperactivity Disorder

Official study title

Investigation of Differences in Dual and Single Motor and Cognitive Tasks of Children With Attention Deficit and Hyperactivity Disorder Compared to Healthy Children

This study has finished and is no longer accepting participants.

In Şehitkamil
ADHDObservational studyAges 7–14
Countries
Türkiye
Sponsor
Gaziantep Islam Science and Technology University
Drug study icon
CompletedNCT00025779

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

Official study title

Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders

This study has finished and is no longer accepting participants.

Multiple locations, including Los Angeles
ADHDMedication studyAges 5–14
Countries
United States
Sponsor
National Institute of Mental Health (NIMH) (Government agency)
Drug study icon
TerminatedEUCTR 2008-003285-26

Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Germany
ADHDHistorical research record
Countries
Germany
Sponsor
Universität Mainz, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und -psychotherapie
Drug study icon
CompletedEUCTR 2013-002720-16

EMPHAS I Evaluation of Methylphenidate (MPH) in adults with ADHD and SUD - clinical pharmacology study A Cross-sectional, Open-label, Non-randomized Single-Center Study on Adults with ADHD and ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Sweden
ADHDHistorical research record
Countries
Sweden
Sponsor
Stockholms Läns Sjukvårdsområde (SLSO)
Drug study icon
CompletedEUCTR 2012-000320-18

Phase shift in adult ADHD of sleep and apetite.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Netherlands
ADHDHistorical research record
Countries
Netherlands
Sponsor
Parnassia Bavo Groep - PsyQ
Drug study icon
Recruitment unclearEUCTR 2005-001909-25

Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

In Norway
ADHDHistorical research record
Countries
Norway
Sponsor
Drug study icon
CompletedNCT07314333

A study to Assess How Centanafadine Interacts With Stimulants in the Body

Official study title

A Phase 1, Single Blind, Parallel-arm Trial to Assess the Potential for Pharmacodynamic Interaction of Centanafadine When Co-administered With Stimulants in Healthy Adults

This study has finished and is no longer accepting participants.

In Salt Lake City
ADHDMedication studyAges 18–55
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00190957

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

Official study title

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial

This study has finished and is no longer accepting participants.

Multiple locations, including El Centro
ADHDMedication studyAges 18+
Countries
United States, Canada
Sponsor
Eli Lilly and Company

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.